Re­searchers use PD-1 check­point drug in pur­suit of a promis­ing cu­ra­tive ap­proach to HIV

The big drug de­vel­op­ers like Gilead and Glax­o­SmithK­line learned years ago how to keep a lid on HIV, but re­searchers re­main chal­lenged by their in­abil­i­ty to root out the la­tent reser­voirs of virus the hide in the cells.

But now in­ves­ti­ga­tors are pur­su­ing a new re­search track that has just demon­strat­ed its po­ten­tial in a can­cer pa­tient in France.

Doc­tors there were treat­ing a lung can­cer pa­tient with HIV with Bris­tol-My­ers Squibb’s Op­di­vo and ob­served a “dras­tic and per­sis­tent de­crease” in the virus hid­den in cells. And there may be a very sim­ple ex­pla­na­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.